STMED was officially established in July 2018 as a technology-driven enterprise in China focused on the R&D and industrialization of life-support medical devices. As the company has expanded, it has successively established R&D centers in Shanghai and Guangzhou, and developed industrial support bases in Suzhou, Wuxi, Huzhou, and Bozhou. This has created an innovative operating model featuring R&D center enablement and coordinated production capacity across multiple locations, and built a fully self-reliant industrial system covering core technology development, precision manufacturing, testing and sterilization, clinical translation, and large-scale delivery.

STMED began its development with the high-technology-barrier ECMO, building a comprehensive proprietary product portfolio to fully meet the core clinical treatment needs of intensive care, emergency medicine, cardiac surgery, and other departments. In February 2023, the company’s independently developed OASSIST® ECMO device was approved for market launch by the National Medical Products Administration, becoming the third domestically produced ECMO device in China and the first in the Yangtze River Delta. The device was subsequently selected as a typical case for the promotion of emergency equipment by the Ministry of Industry and Information Technology and included in the catalog of outstanding domestically produced medical devices. It has also received numerous honors, including the First Major Equipment Set of Jiangsu Province and the Third Prize of the Jiangsu Provincial Science and Technology Award. It is now widely used in numerous Grade III Class A hospitals across China and has accumulated extensive successful case experience in critical care treatment.